COSM vs PHVS vs HROW vs KALV

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus 2. 0% for Cosmos Health Inc. (COSM). Analysts rate Pharvaris N. V. (PHVS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -94. 5% for Cosmos Health Inc. (COSM). Over 10 years, the gap is even starker: HROW returned +914. 3% versus PHVS's +2. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), KalVista Pharmaceuticals, Inc.

(KALV) is the lower-risk stock at 0. 82β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 158% more volatile than KALV relative to the S&P 500. On balance sheet safety, Pharvaris N. V. (PHVS) carries a lower debt/equity ratio of 0% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus 2. 0% for Cosmos Health Inc. (COSM). On earnings-per-share growth, the picture is similar: Harrow Health, Inc. grew EPS 71. 4% year-over-year, compared to -7. 3% for KalVista Pharmaceuticals, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pharvaris N.

V. (PHVS) is the more profitable company, earning 0. 0% net margin versus -1391. 1% for KalVista Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HROW leads at 11. 2% versus -1343. 0% for KALV. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for HROW: 93.

8% to $75. 67.

In this comparison, COSM (92.

4% yield) pays a dividend. PHVS, HROW, KALV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, KalVista Pharmaceuticals, Inc.

(KALV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82), +154. 5% 10Y return). Harrow Health, Inc. (HROW) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KALV: +154. 5%, HROW: +914. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COSM is a small-cap income-oriented stock; PHVS is a small-cap quality compounder stock; HROW is a small-cap high-growth stock; KALV is a small-cap quality compounder stock. COSM pays a dividend while PHVS, HROW, KALV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.